HCA Florida Largo Hospital participates in groundbreaking clinical study providing new option for high-risk cardiac patients
HCA Florida Largo Hospital, in collaboration with the HCA Healthcare Research Institute, announces its participation in the revolutionary TRICAV I clinical study, aimed at enhancing outcomes for patients suffering from severe tricuspid regurgitation (TR).
Tricuspid regurgitation, also known as a leaky triscusupid valve, is a type of heart valve disease that affects more than 1.6 million people in the United States. If left untreated, possible complications may include irregular heartbeat and heart failure.
The TRICAV I study trial evaluates the TricValve® Transcatheter Bicaval Valve System, a cutting-edge bicaval transcatheter tricuspid valve replacement technology. This procedure is designed for patients who have been considered a high risk for surgery. The TricValve® system offers a minimally invasive solution by implanting prosthetic valves into the superior and inferior vena cava — without disturbing the native tricuspid valve.
For patients like Jim Byers who was not a candidate for another heart surgery, this procedure is life-changing. “When I first met Dr. Sanon, I was extremely impressed with his patience and his doctor to patient communication skills. I was facing a medical crisis that could have resulted in my death,” shared Byers. “Dr. Sanon literally saved my life and will be able to save the lives of others because of the success of the TricValve trial.”
“This study represents a major leap forward in how we treat complex tricuspid valve disease and adds another resource in our structural heart toolkit,” said Dr. Saurabh Sanon, structural interventional cardiologist. “By offering access to revolutionary research at HCA Florida Largo Hospital, we’re not only improving individual patient outcomes — we’re shaping the future of cardiovascular medicine.”
“By investing in groundbreaking heart studies and clinical innovation, we’re not only advancing medical knowledge, we’re bringing the latest treatment options directly to our patients. This commitment ensures our community has access to the highest level of care today, while shaping the future of medicine for tomorrow” shared Dr. Sebastian Strom, chief executive officer at HCA Florida Largo Hospital.
The clinical trial will follow patients for up to five years, collecting long-term safety and efficacy data to advance the future of cardiac intervention. Patients should speak with their physician if they think they may be a candidate for this study.